NeuroGenomeX is a drug discovery company developing novel treatments for diseases of the brain and nervous system. The current NeuroGenomeX discovery program is focused on therapeutic target areas of epilepsy and traumatic brain injury. NeuroGenomeX is advancing its lead drug candidate, 2-deoxy-D-glucose (2DG), as an anticonvulsant that stops seizures and has beneficial effects against adverse long-term consequences of epilepsy. 2DG also has shown favorable therapeutic neuroprotective effects in animal models of traumatic brain injury (TBI).
NeuroGenomeX Frequently Asked Questions (FAQ)
Where is NeuroGenomeX's headquarters?
NeuroGenomeX's headquarters is located at P.O. Box 14211, Madison.
What is NeuroGenomeX's latest funding round?
NeuroGenomeX's latest funding round is Other Investors.
Who are the investors of NeuroGenomeX?
Investors of NeuroGenomeX include Wisconsin Alumni Research Foundation.
Who are NeuroGenomeX's competitors?
Competitors of NeuroGenomeX include TheraVida, Armgo Pharma, Amplyx Pharmaceuticals, Presage Biosciences, Foamix Pharmaceuticals and 7 more.
Compare NeuroGenomeX to Competitors
Solidus Biosciences is a company focused on providing business intelligence in the pharmaceutical and biologic drugs sector. The company's main services include offering insights on life cycle management, brand erosion, generic entry, biosimilars, patents, sales, litigation, and more, all related to pharmaceutical and biologic drugs. The company primarily serves the biopharmaceutical industry. It is based in Troy, New York.
CNS is a company developing and marketing a neurophysiological bio-marker system which can objectively measure the physiological effects of psychiatric drugs on humans.
Paloma Pharmaceuticals, Inc. is a drug development company focusing on pathologies with a vascular component including cancer, ocular diseases (macular degeneration and diabetic retinopathy), arthritis, fibrotic diseases (pulmonary fibrosis) endometriosis, osteoporosis and skin diseases (psoriasis and atopic dermatitis). Paloma owns the intellectual property relating to a series of , small molecule drugs created through an integrated design platform incorporating , customized and industry standard computational tools that has therapeutic potential for the treatment of the foregoing diseases.
TheraVida develops therapeutic drugs intended for the treatment of hyperhidrosis. Its products help healthcare providers to treat urological disorders and improve the lives of patients. The company was founded in 2005 and is based in Chapel Road, North Carolina.
Optimata Ltd. is a privately-owned science-based interdisciplinary company engaged in biosimulation technology for optimizing drug treatment protocols. Optimata partners with pharmaceutical and biotechnology companies to develop effective new treatments for diseases by simulating disease processes. This aims to reduce time-to-market and development costs while improving the competitive profile of the newly developed drug.
Salzburg Therapeutics is a drug development company that is developing Cytotoxamer and Genotoxamer products for cancer treatment. The company's technology aims to provide a solution for delivering activated forms of anticancer drugs, nanoparticles, and other moieties specifically to cancer cells.